GE Healthcare rolls out new R&D partnership in Turkey

Turkish flag blowing in the wind

Turkey may be Europe's sixth largest pharmaceutical industry, but it's looking to ascend the ranks with a boost from GE Healthcare ($GE). The company has launched a new collaborative research scheme to support Turkey's bioprocessing development and manufacturing.

The scheme is offered through GE's Fast Trak Bioprocessing Technology and Training Laboratory, based at the company's Turkey Innovation Center in Istanbul, the company said in a statement. The facility joins similar sites in the U.S., U.K., China, India and Sweden, and offers access to GE Healthcare's technology for drug discovery, protein science and bioprocessing research.

While the lab has already offered customers practical training and process development, it will now be available to successful applicants from universities and research institutions, complementing Turkey's Scientific and Technological Research Council's strategy to support R&D growth, which includes grant programs and industry-academia partnerships.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

And it doesn't just offer access to equipment--it's also staffed by a team of local GE bioprocessing experts who can help build up the biomanufacturing skills base in Turkey.

About 3% to 4% of Turkey's exports are made up of "high-tech products," said Hasan Ali Çelik, Turkey's deputy minister of science, industry and technology, at the site's inauguration. Çelik wants to bump this up to 15% by focusing on the "critical sector" that is biopharma.

"We believe the products which will be developed in this laboratory will provide significant contribution to Turkey's economy and offer important services to humanity," Çelik said.

- here's the statement

Suggested Articles

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.